What it's for (Indications)
- Antazoline phosphate 0.
- 05% and Tetrahydrozoline hydrochloride 0.
- 04% ophthalmic solution is indicated for the temporary relief of discomfort and redness due to minor eye irritations.
- Specifically, it is used for the symptomatic treatment of allergic conjunctivitis, providing relief from itching, burning, watering, and hyperemia of the conjunctiva.
- This combination targets both the histamine-mediated allergic response (antazoline) and the vascular congestion leading to redness (tetrahydrozoline), offering comprehensive relief for ocular allergy symptoms.
- It is intended for short-term use and should be used under the guidance of a healthcare professional to ensure proper diagnosis and management of ocular conditions, especially since symptoms of minor eye irritations can sometimes mask more serious underlying ophthalmic pathologies requiring different therapeutic approaches.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For adults and children 6 years of age and older, the typical recommended dosage is 1 or 2 drops instilled into the conjunctival sac of the affected eye(s) two to four times daily, or as directed by a physician. The duration of treatment should generally be limited to short-term use, typically no longer than 3 to 5 days, to avoid potential rebound hyperemia and other adverse effects associated with prolonged use of vasoconstrictors. Patients should be advised to remove contact lenses prior to administration and wait at least 15 minutes before reinserting them. It is crucial not to exceed the recommended dosage or duration without medical supervision due to the risk of systemic absorption and associated adverse effects, particularly in vulnerable populations. Adherence to prescribed frequency and duration is paramount to minimize risks and maximize therapeutic benefits. |
Safety & Warnings
Common Side Effects
- Commonly reported adverse effects associated with antazoline + tetrahydrozoline ophthalmic solution include transient ocular stinging or burning upon instillation, blurred vision, pupillary dilation (mydriasis), and irritation.
- Less frequently, patients may experience punctate keratitis, lacrimation, or increased intraocular pressure.
- Systemic absorption, though uncommon with ophthalmic use when dosed appropriately, can lead to systemic effects, particularly with overuse or in susceptible individuals.
- These may include headache, dizziness, drowsiness or sedation (primarily due to antazoline), nausea, tremors, and systemic sympathomimetic effects such as palpitations, tachycardia, hypertension, and sweating (due to tetrahydrozoline).
- Pediatric patients, especially infants and young children, are particularly vulnerable to severe systemic adverse effects from tetrahydrozoline, including profound central nervous system depression, which can be life-threatening.
- Any severe or persistent adverse effects warrant immediate medical consultation.
Serious Warnings
- Black Box Warning: This specific ophthalmic combination product, Antazoline + Tetrahydrozoline, does not carry an official FDA Black Box Warning. However, due to the potential for serious adverse effects, especially with misuse, overdose, or in vulnerable populations, a 'Serious Warnings' advisory is highly pertinent. There is a significant risk of systemic absorption of tetrahydrozoline, particularly in infants and young children, which can lead to profound central nervous system depression, including drowsiness, coma, respiratory depression, bradycardia, and hypothermia, necessitating immediate medical intervention. Accidental ingestion or excessive ocular use in this age group has been associated with severe toxicity, hospitalizations, and fatalities. Overdosage in adults can also lead to systemic sympathomimetic effects. Furthermore, prolonged or excessive use in adults can lead to rebound conjunctival hyperemia, masking underlying ocular conditions, and systemic effects such as hypertension, tachycardia, and headaches. Patients should be explicitly cautioned against exceeding recommended dosages or durations of use, and strict supervision is advised when administered to children over 6 years. KEEP THIS MEDICATION OUT OF THE REACH OF CHILDREN AT ALL TIMES.
- Patients should be advised that use of this product beyond the recommended dosage or duration, or in the presence of serious eye conditions, may mask more severe underlying ocular pathology or lead to significant adverse effects.
- Prolonged use of ocular vasoconstrictors like tetrahydrozoline can result in rebound conjunctival hyperemia, where chronic redness and irritation worsen upon cessation of the medication, potentially leading to drug-induced chronic conjunctivitis.
- Caution is warranted in patients with cardiovascular disease, hypertension, hyperthyroidism, diabetes, or those receiving monoamine oxidase inhibitors (MAOIs) or other medications that may elevate blood pressure, due to the potential for systemic absorption of tetrahydrozoline, which can exacerbate these conditions.
- Discontinue use and consult a physician if symptoms worsen, persist for more than 72 hours, or if eye pain, changes in vision, continued redness or irritation of the eye occurs.
- Contact lens wearers should exercise caution and remove lenses before instillation.
- Always consult a healthcare provider for persistent or worsening eye symptoms.
How it Works (Mechanism of Action)
This ophthalmic preparation combines two active pharmacological agents: antazoline phosphate and tetrahydrozoline hydrochloride, each targeting distinct pathways involved in allergic conjunctivitis. Antazoline phosphate is an antihistamine that acts as a competitive H1-receptor antagonist. It blocks the effects of histamine released during allergic reactions by occupying histamine receptor sites, thereby reducing pruritus (itching), lacrimation (watering), and swelling associated with ocular allergies. Tetrahydrozoline hydrochloride is an alpha-adrenergic agonist, a sympathomimetic agent. Its primary action is to cause vasoconstriction of the small arterioles in the conjunctiva by stimulating alpha-adrenergic receptors. This vasoconstrictive effect reduces conjunctival hyperemia (redness) and mild edema, contributing to a clearer appearance of the eye. The synergistic action of these two compounds provides comprehensive relief from the multifactorial symptoms of allergic conjunctivitis by addressing both the allergic inflammatory response and the vascular congestion.
Commercial Brands (Alternatives)
No other brands found for this formula.